Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines

Chinese Medical Journal

Volumn 116, Issue 11, 2003, Pages 1673-1677

  Xu, Kexin ^a   Wang, Xianghong ^b   Ling, Mingtat ^b   Wong, Yongchuan ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adrenergic receptor antagonist; Drug effects; Prostate cancer

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; PROTEIN P21; PROTEIN P27; TERAZOSIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TARGETING; HORMONE RESPONSE; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

EID: 0346896393     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pienta KJ. Prostate Cancer. In: Walsh PC, Retik AB, Stamey TA, et al. eds. Compbell's Urology, 5th ed. Philadelphia: Saunders, 1998:2489-2496.
2. Berges RR, Vukanovic J, Epstein JI, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-480.
3. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 1997;65:284-297.
4. Wang X, Masters JR, Wong YC, et al. Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells. Anticancer Res 2001;21:403-408.
5. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78: 59-66.
6. Jarrard DF, Bova GS, Ewing CM, et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 1997;19:90-96.
7. Gu FL. The epidemiology and natural history of prostate cancer. In: Guo Yinglu, eds. Benign prostatic hyperplasia and prostate cancer. (Chin) Beijing: Publishing Company for Public Health, 1998:131-140.
8. Kirby RS, Christmas TJ, Brawer MK. Management of hormone-refractory prostate cancer. In: Kirby RS, Christmas TJ, Brawer MK, eds. Prostate Cancer 2nd ed. London: Mosby 2001:187-198.
9. Sediman AD, Scher HI, Petrylak D, et al. Estamustine and vinblastine: use of prostate-specific antigen as a clinical trial end point for hormane refrectory prostatic cancer. J Urol 1992;147:931-934.
10. Pienta KJ, Redman BG, Hussain M, et al. A combination of estramustine and ectoposide orally may be an effective regimen in the treatment of hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1993;12:246-251.
11. Neer EJ. Heterotrimeric G-protein. Organizations of transmembrane signals. Cell 1995;80:249-257.
12. Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate 1997;30:202-215.
13. Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17: 641-649.
14. Kirby RS, Pool JL. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 1997;80:521-532.
15. Kyprianou N, Bruckheimer EM, Goo Y. Cell proliferation and apoptosis in prostate cancer: significance in disease progression and therapy. Histol Histopathol 2000;15:1211-1223.
16. Kyprianou N, Chon J, Benning CM. Effects of alpha 1-adrenoceptor α antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate 2000;9:42-46.
17. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000;60:4550-4555.
18. Chon JK, Borkowski A, Partin AW, et al. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999;161: 2002-2008.
19. Mahyar-Roemer M, Roemer K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001;20:3387-3398.
20. Philipp-Staheli J, Payne SR, Kemp CJ. p27 (Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001;264:148-168.
21. Katayose Y, Kim M, Rakkar AN, et al. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57:5441-5445.
22. Craig C, Wersto R, Kim M, et al. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997;14:2283-2289.
23. Fujieda S, Inuzuka M, Tanaka N, et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999;84: 315-320.
24. Patel SD, Tran AC, Ge Y, et al. The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene. Mol Ther 2000;2:161-169.